40 Posts Not To Miss From ESMO24 Day 3

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.

This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.

The congress featured nearly 300 sessions, presenting over 2,000 abstracts, with a focus on the latest advancements in cancer research and treatment. Key topics included new therapeutic combinations for various cancers, the long-term effects of immunotherapy, and innovative approaches integrating artificial intelligence into cancer care.

Here are some highlights from ESMO Congress 2024 Day 3:

Sumanta Pal:

“Amazing overview of non-clear cell kidney cancer by Pedro Barata at ESMO24. Spanning papillary, chromophobe, collecting duct, RMC and multiple other subtypes, he eloquently provides perspective on optimal management based on available data for each disease state. The bottom line: we need more dedicated trials in this space!”

Rachel Riechelmann:

“New 1L SoC in metastatic anal cancer : Retifanlimab + CarboTax vs CarboTax:

• PFS: 9.3 vs 7.4 mo
• OS trend: 23 vs 29 mo
• ORR: 48% vs 36%

Congrats Sheela Rao et al.

Just missed participation of countries where #analcancer is frequent (Brazil, South Africa).”

Giovanni Maria Iannantuono:

“Huge congrats to Andrea Apolo, an incredible physician-scientist and a true leader dedicated to improve the life of bladder cancer patients.”

Stephen Liu:

“At the Palau Nacional for the ESMO24 Presidential Dinner with Thoracic Oncology royalty!”

Erika Hamilton:

“Masterful discussion of ILD with TDXd by Dr. Pat LoRusso.

HER ‘low’ expression in lungs – likely why worse with TDXd than other ADC targets.

Ethnicities such as Japanese at higher risk.

Prior ILD, hepatic and renal impairment all risk factors.”

Caterina Sposetti:

“Kudos to Dr. Ligibel’s presentation of BWEL phase III trial results at ESMO24: a 2y telephone-based weight loss intervention significantly increase physical activity habits in overweight women with early Breast Cancer (+39.5 min/wk, p=0.0004).”

Jason Brown:

“VOLGA data with Durvalumab + Tremilimumab +/- EV presented by Alexandra Drakaki.

• 70% patients with ctDNA clearance.
• 3 patients without clearance upstaged at cystectomy.
• Better EFS if baseline ctDNA negative or clearance.”

Neeraj Agarwal:

“ESMO presidential dinner ESMO President Andres Cervantes‘s provided the stats on the ESMO24 meeting: record breaking number of abstract submission (>5000), invited speakers (>600), and membership >40k. Amazing job by various committees to make it so successful. Congrats!”

Edgardo Santos:

“A very interesting and innovative technology using artificial intelligence trained model to identify symptomatic pneumonitis, an unmet need in our thoracic clinics presented by Dr. Naidoo.”

Eda Eylemer Mocan:

“CONTACT-02 day 3 ESMO24

Cabo+atezo vs NHT in mCRPC

• met one of the PEP, PFS HR:0.65
• OS did not statisticle
• ‼️‼️except liver and bone mets

May be useful progressed on an NHT.”

Oriol Mirallas:

“Drug Development track

SHR1904: ADC-CLDN18.2-TOPI

• At 6mg/kg ORR 56%, DCR 89%
• G3 3%
• Dr. Xu

DS-9606: ADC-CLDN6-TOPI

• 4PR
• >56% HGOC+GCT
• G3 16.7%, cutaneous tox!
• Dr. Patel

Discussed by Cinta Hierro Carbo.”

Neeraj Agarwal:

“Breaking news (practice changing) from ESMO24.

Tom Powles presents the 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +|- durvalumab in MIBC bladder cancer.

Significant improvement in DFS (HR 0.68) & OS (HR 0.75) with durvalumab.”

The NIAGARA trial (NCT03732677) is a phase III, randomized, open-label, multicenter, international study set to enroll approximately 1,050 patients with muscle-invasive bladder cancer (MIBC).

Participants, prior to undergoing radical cystectomy, will be randomly assigned in a 1:1 ratio to receive either durvalumab combined with gemcitabine and cisplatin (Arm 1) or gemcitabine and cisplatin alone (Arm 2).

Tom Powles:

“The 1st disitimab Vedotin (HER-2 MMAE ADC) and pembro showing 1st line response rates of 75% in HER 1-3+ UC. Toxicity profile looks distinct from EV (fatigue>skin). There is a global randomised phase 3 of DV & pembro vs standard chemotherapy.”

Karine Tawagi:

“Composition of intestinal microbiota plays impt role in IO response.

Dr. Ciccarese on ph 2 TACITO:

• Tx naive mRCC for axi/pembro received FMT from IO responding pt (who had CR) vs placebo
• 1 yr PFS rate of 66.7% vs 35.0%, median PFS 14.2 vs 9.2mo
• No AE or inc in irAE.”

Roberto Borea:

“Presidential symposium with Marleen Kok discussing update OS analysis of KEYNOTE522.

KN522 changed eTNBC clinical practice but we still need biomarker to tailor treatment!”

Pierre Blanchard:

“Major congrats to my friend Dr. Sofia Rivera on the HypoG-01 just presented at ESMO2024.

Hypofractionation not inferior to conventional fractionation for Breast Cancer with nodal RT.

• Similar toxicity
• Similar efficacy (BCSM OS LRFS DMFS)

3 weeks is the way to go!”

Toni Choueiri:

“KEYNOTE-522 shows that the addition of neoadjuvant + adjuvant pembro to neoadjuvant chemo leads to a significant and meaningful improvement in OS [HR, 0.66 (0.95% CI, 0.50-0.87); P=0.0015] in patients with high-risk early-stage TNBC!”

Hope Rugo:

“Peter Schmid presents the OS data from KN522 ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% OS with pembro pre/post op for TNBC. Patients with PCR had 95% survival +/-pembro but 6% OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers!”

Jason Brown:

“The awaited Niagara results are here Tom Powles. Perioperative Durvalumab shows clear PFS and OS benefit in MIBC.

• pCR rate 33%
• ‼️PFS HR 0.68
• OS HR 0.75
• Is adjuvant IO needed for all patients?”

Pierre Blanchard:

“Dr. Grist at ESMO2024.

Decipher by Veracyte, DECIPHER prognostic for OS in mHSPC but most importantly predictive for efficacy of docetaxel.

Not predictive for Abi effect.”

Erika Hamilton:

“KN522 OS data 5 yrs after the initial pCR presentation

75 months of f/u for chemo +/ pembro I stage II and III TNBC

• EFS is stable from before with 9% improvement with pembro
• OS improved by 5% (81.7-> 86.6%).”

Oriol Mirallas:

“PRESIDENTIAL Session ESMO24

NIAGARA: Durva+CisGemx4>IQ->Dura 8 cycles
cT2-4N1/0M0 #UC

• EFS 67.8 vs 59.8% 2yrs HR 0.68
• OS 82.2vs 75.2% 2yrs HR 0.75
• High PDL1expr
• NEW SoC MIBC.”

Ishwaria Subbiah:

” ‘What can we do to help individuals, systems, and societies?’ The question to kickoff the ESMO Resilience Task Force Special Open Forum from chair Dr. Banerjee on Sustaining the oncology workforce and tackling burnout in oncology and medicine as a whole!

Looking forward to the insights of Matteo Lambertini, Jon Lim, Jean-Yves Blay, Konstantinos Kamposioras and Maria Elena Elez Fernandez.”

Cholangiocarcinoma Foundation:

“We’re proud to see Angela Lamarca as a discussant at the Presidential Session of ESMO 2024. Her dedication to advancing cancer research and improving patient outcomes is inspiring.”

Smitha Krishnamurthi:

“NICHE2: 3yDFS 100%
+ rapid ctDNA clearance

NICHE 3 relatlimab+nivo: 68% pCR similar to NICHE2 but numerically gr 3-4AE

IMHOTEP: pCR 53% with 1-2 doses pembro.

MyriamChalabi, Dr. Peter de Gooyer, Christelle de la Fouchardiere.

Superb discussion by Jenny Seligmann.”

Roberto Iacovelli:

“After years and years of inconclusive trials in adjuvant tx of MIBC and few evidence in adjuvant therapy,
Tom Powles and NIAGARA study team show us the way to increas OS in bladder cancer and save lives!”

Sabine Brookman-May:

“The right questions addressed by Petros Grivas after NIAGARA trial presentation:

• should we proceed with adjuvant treatment in ypT0?
• Is there a role of ctDNA for adjuvant treatment decisions
• can patients be cured with systemic therapy Bladder Sparing approach?”

Enrique Grande:

“NIAGARA is the first randomized trial to demonstrate significant OS difference in the NIBC perioperative trest.
Tom Powles did it again!!! Another practice changing trial in the back.”

Luca Arecco:

“Amazing discussion by Marleen Kok on the OS results of (neo)adjuvant Pembrolizumab in early TNBC.

• KN522 soc in early TNBC
• Need to improve our knowledge on biomarkers and long-term toxicity of immunotherapy, including on fertility in younger patients.”

Daniel Castellano:

“NIAGARA phase III study in MIBC show 3 different important Practice changing!

• first phase III study with > 1000 pts randomized in neoadjuvant chemo with + OS
• the addition of IO therapy (durvalumab) as neoadj and adj setting
• the perioperative strategy for MIBC as pre and post surgery journey!”

Bárbara Melão:

“SPLASH at ESMO24.
Phase III trial for mCRPC patients PSMA+, after ARPI, in the pre-chemotherapy setting

• 2:1 to Lu-PSMA-I&T (4 cycles) vs alternative ARPI
• Primary endpoint: rPFS
• 412 men, crossover was 84.6%
• HR for rPFS 0.71 (p=0.0088)
• No OS benefit is this first interim analysis
• TEAEs were lover with Lu-PSMA (30.1 vs 36.9%).”

Elisa Agostinetto:

“At ESMO24, overall survival results of KEYNOTE-522

With 75 months follow-up, the addition of (neo)adjuvant pembrolizumab to CT significantly improves OS (HR 0.66), consistently across subgroups.

Updated data confirms EFS benefit (HR 0.65).

No new safety signals.”

Evelyn Wong:

“A framework to predict the future of tissue agnostic drug development – Vivek Subbiah calling upon the community to address the unknowns – to push for more regulatory discussions and approvals.”

Daniel Gerlach:

“Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic, colorectal, and non-small cell lung cancer.”

Stephen Liu:

“Dr. Jarushka Naidoo with a masterful presentation on an AI-aided quantitative radiomics tool for pneumonitis after chemoradiation for stage III NSCLC. Reticulation volume important marker of risk, high lung volumes seem protective. Potential tool to predict toxicity?”

Arndt Vogel:

“Neoadjuvant nivolumab plus relatlimab in MMR-deficient colon cancer

NICHE-3 study

• 97% PR
• 92% MPR, 68% pCR
• 98% DFS
• low rate of AEs, highly effective.”

Hope Rugo:

“ESMO24 beautiful discussion by Marleen Kok on KN522 OS presentation highlighting impact on young women, importance of QOL and urgent need for Biomarker research.”

Susana Banerjee:

“Thanks to great panel and audience RTF, ESMO24 forum addressing burnout and resilience together. Join us at the first resilience ESMO workshop in Barcelona 31st Jan/1st Feb 2025.”

Stephanie Graff:

“Petros Grivas gives Tom Powles et al his wish list for questions for NIAGARA and outlines ongoing questions in the wider field.

(Love seeing my ASCO LDP classmate leading a great discussion!)”

Jason Brown:

“Disitimab vedotin + Pembrolizumab in 1L treatment for mUC presented by Matt Galsky. Thrilled to have participated in this trial University Hospitals, Case Comp Cancer Ctr.

• HER2 is important target even in HER2 low patient
• 75.0% ORR, 35% CR
• DV + P vs DV randomization ongoing.”

45 Posts Not To Miss From ESMO24 Day 1
43 Posts Not To Miss From ESMO24 Day 2

More posts featuring ESMO24 on oncodaily.com